Adjuvant Capital related stories
All articles and analysis
Adjuvant rakes in $300m for debut public health fundAdjuvant Capital has raised $300 million for its new venture fund focused on improving global public health.
Frontier Nutrition pulls in $6m Series BFrontier Nutrition, an India-based maker of fortified snacks, has raised $6 million in Series B financing.
MinervaX attracts $57m Series BMinervaX, a Danish biotechnology company, has raised $57 million in Series B financing.
- MSD to buy VC-backed Themis
MSD has agreed to acquire Vienna-based Themis, a provider of immunomodulation therapies for infectious diseases and cancer.
- ChromaCode scores $10m
ChromaCode Inc, a software and reagent technology company, has secured $10 million in a Series C extension.
- Adjuvant Capital leads Series A round for 54gene
54gene, an African genomics research, services and development company, has raised $15 million in Series A funding.
- Codagenix lands $20 mln Series B
Farmingdale, New York-based Codagenix Inc, a developer of prophylactic vaccines and oncolytic virus therapies, has raised $20 million in Series B funding.
AN2 Therapeutics scores $12 mln Series ACalifornia-based AN2 Therapeutics Inc, a biopharmaceutical company focused on infectious diseases, has raised $12 million in Series A financing. Mountain Group Partners led the round with participation from Adjuvant Capital, Brii Biosciences and BioRock Ventures.
- AN2 Therapeutics scores $12 mln Series A
California-based AN2 Therapeutics Inc, a biopharmaceutical company focused on infectious diseases, has raised $12 million in Series A financing. Mountain Group Partners led the round with participation from Adjuvant Capital, Brii Biosciences and BioRock Ventures.
- Themis raises 40 mln euros
Themis said Sept. 18 that it raised 40 million euros ($44 million) in a Series D round of funding co-led by new investors, Farallon Capital and Hadean Ventures. MSD (tradename of Merck & Co Inc, Kenilworth NJ USA) and Adjuvant Capital, as well as current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences, also participated. Themis develops immunomodulation therapies for infectious diseases and cancer.